Merck Serono, Compugen Form Biomarker Discovery Firm | GenomeWeb

NEW YORK (GenomeWeb News) – Merck Serono and Compugen jointly announced today the formation of a new biomarker discovery firm focused on prediction of drug-induced toxicity.

The new venture, called Neviah Genomics, will operate out of the Merck Serono Israel Bioincubator and will receive funding from Merck Serono Ventures. Tel Aviv, Israel-based Compugen will provide predictive discovery technologies to the venture and will receive an undisclosed equity stake in the company and rights to royalties from potential future sales. Further terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.